Does erenumab suspension affect chronic migraine course? A real life experience
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts | The Journal of Headache and Pain | Full Text
Migraine: integrated approaches to clinical management and emerging treatments - The Lancet
PDF) Psychological Predictors of Negative Treatment Outcome with Erenumab in Chronic Migraine: Data From an Open Label Long-Term Prospective Study
Getting closer to a cure for migraine | Nature Reviews Neurology
Does erenumab suspension affect chronic migraine course? A real life experience
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment - The Lancet Neurology
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label
PDF) Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real‐World Case Series
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
Full article: A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study - Bianca Raffaelli, Maria Terhart, Lucas Hendrik Overeem, Jasper Mecklenburg, Lars Neeb, Maureen Steinicke, Uwe Reuter, 2022
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
PDF) A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine
Headache & Migraine Archives - Medical Conferences
60th Annual Scientific Meeting American Headache Society® June 28‐July 1, 2018 San Francisco Marriott Marquis San Francisco, CA - 2018 - Headache: The Journal of Head and Face Pain - Wiley Online Library
IHC 2019 Late Breaking Abstracts, 2019
Does erenumab suspension affect chronic migraine course? A real life experience
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study | The Journal of Headache and Pain | Full Text
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
